Oragenics licenses Inspirevax intranasal adjuvant BDX301 for COVID-19 vaccine candidate NT-CoV2-1

ORAGENICS INC

Upfront fee $50K; milestones up to $5.3M including $2M on first US sale; tiered royalties 7% net sales (decreasing to 4%).
Development milestones: first patient in clinical study by Dec 31, 2023; Phase 2a by Sep 30, 2024; Phase 3 by Dec 31, 2026; marketing app by Jun 30, 2028.
Preclinical GLP toxicology study in rabbits showed no toxicity signals or adverse events for NT-CoV2-1 plus BDX301.
Companies to form Joint Development Committee; option to expand collaboration to other intranasal vaccine candidates.
Oragenics to provide program update in mid-2023.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ORAGENICS INC entered into License Agreement with Inspirevax Inc. valued at $50,000 (effective 2023-02-23).

Action: entry
Agreement: license
Counterparty: Inspirevax Inc.
Value: $50,000
Effective: 2023-02-23

Exact text from the filing

On February 23, 2023, the Company entered into a Commercial License Agreement (the “License Agreement”) with Inspirevax Inc. (“Inspirevax”) pursuant to which Inspirevax granted the Company an exclusive worldwide license to use Inspirevax’s inventions, patents, trade secrets, know-how, copyright, biological material, designs, and/or technical information created by or on behalf of Inspirevax (the “Inspirevax Technologies”) relating to its novel lipid-protein based intranasal adjuvants, to make, research, and develop an intra-nasal vaccine in combination with an antigen (“Combination Product”) to be used in an intranasal vaccine for use against diseases caused by coronaviruses and any genetic variants thereof to be sold by us. As consideration for the grant of the license, the Company will pay an upfront signing fee of $50,000.

View on SEC.gov

197 material agreements filed in the last 30 days. Browse all material agreements →

ORAGENICS INC filing history →

Source: SEC EDGAR

accession 0001493152-23-006354

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.